ImmunAbs

ImmunAbs focuses on developing antibody drugs for the treatment of autoimmune diseases, diabetic retinopathy, and metabolic syndromes. The company's business model centers on the research and development of a pipeline of therapeutic candidates, funded through a combination of equity financing and national grants. Since its inception, ImmunAbs has secured significant funding, including a Seed Round in 2019 for $5.56M, a Series A in 2021 for $9.9M, and a Series B in 2022 for $9.3M, with investors like CKD Venture Capital, DTN Investment, and Hana Securities. The company aims to form global partnerships to accelerate its drug candidates toward market availability.

The lead product in the company's pipeline is IM-101, a humanized monoclonal antibody designed to treat severe autoimmune diseases by targeting complement C5. This antibody binds to a different site on the C5 protein than existing treatments, with the potential for higher efficacy. IM-101 is being developed to address conditions like Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria (PNH), where the body's complement system incorrectly attacks its own cells. In early 2024, ImmunAbs successfully completed a Phase 1 clinical trial in the U.S., which demonstrated a favorable safety profile for IM-101. Following this, the company received FDA clearance for a Phase 2 Investigational New Drug (IND) application to further evaluate the efficacy of IM-101 in treating Myasthenia Gravis. Another key candidate is IM-201, which targets diabetic retinopathy by aiming to normalize pathological blood vessels and inhibit disease recurrence.